Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | TACR2 | P21452 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19986529 | 0.94 | PTGS2 (0.56) | CYP3A4TSHRNLRP3ALDH1A1LMNA | |
| SCHEMBL9274463 | 0.89 | HPGD (0.50) | ALDH1A1LMNAMEN1MAPTALOX12 | |
| SCHEMBL24570956 | 0.85 | MAPT (0.55) | TSHRALDH1A1LMNAMEN1MAPT | |
| SCHEMBL6331942 | 0.83 | CYP3A4 (0.63) | CYP3A4TSHRNLRP3ALDH1A1MEN1 | |
| SCHEMBL1033939 | 0.83 | NPSR1 (0.58) | CYP3A4ALDH1A1LMNAMEN1MAPT | |
| SCHEMBL1423027 | 0.82 | UNG (0.54) | CYP3A4ALDH1A1LMNAESR1ADRA2A | |
| SCHEMBL2539187 | 0.81 | TRPV1 (0.58) | TSHRALDH1A1LMNAMEN1MAPT | |
| SCHEMBL27541001 | 0.81 | MAPT (0.56) | ALDH1A1LMNAMEN1MAPTALOX12 | |
| SCHEMBL14127779 | 0.81 | HPGD (0.58) | ALDH1A1LMNAMEN1MAPTALOX12 | |
| SCHEMBL48879 | 0.81 | HPGD (0.58) | ALDH1A1LMNAMEN1MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1794989-A | N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulfonyl)phenylalanine derivatives and related compounds for the treatment of diabetes | INST PHARMACEUTICAL DISCOVERY (US) | 2006-06-28 | — | — | CN | claimed |
| JP-58057464-A | — | — | None | — | — | JP | disclosed |
| CN-1794989-A | N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulfonyl)phenylalanine derivatives and related compounds for the treatment of diabetes | INST PHARMACEUTICAL DISCOVERY (US) | 2006-06-28 | — | — | CN | disclosed |
| US-6919357-B2 | α adrenergic agents | MOLECULAR DESIGN INTERNATIONAL INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1418907-A4 | NOVEL ALPHA ADRENERGIC AGENTS | MOLECULAR DESIGN INTERNAT INC (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1418907-A1 | NOVEL ALPHA ADRENERGIC AGENTS | Molecular Design International Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030092741-A1 | Novel alpha adrenergic agents | MOLECTULAR DESIGN INTERNATIONAL INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003013515-A1 | NOVEL ALPHA ADRENERGIC AGENTS | MOLECTULAR DESIGN INTERNATIONAL INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| JP-S5857464-A | NOVEL FLUORAN DERIVATIVE | RICOH CO LTD | 1983-04-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092741-A1 | Novel alpha adrenergic agents | ADRA1D, ADRB1, ADRA1B | CYP3A4 1191/4885TSHR 3454/4885NLRP3 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.